Eisai Buys U.S. Biotech AkaRx With Chinese And Indian Markets In Sight
This article was originally published in PharmAsia News
Executive Summary
Eisai plans to acquire U.S. biotech AkaRx for $225 million in a move that will give the Japanese outfit access to AKR-501, a novel small-molecule thrombopoietin mimetic under development to treat thrombocytopenia resulting from viral hepatitis and other problems
You may also be interested in...
Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound
Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.
Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound
Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.
Start-Up Quarterly Statistics, Q4 2009
Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.